

11 Anhang

Eigene Publikationen

Übersicht

Erstautorenschaften Originalarbeiten

1. Sturm I, Rau B, Schlag P, Wust P, Hildebrandt B, Riess H, Hauptmann S, Dörken B, Daniel PT. Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy. *BMC Cancer* 2006, 6:124
2. Sturm I, Stephan C, Gillissen B, Siebert R, Radetzki S, Hauptmann S, Jung K, Loening S, Dörken B, Daniel PT. Loss of the tissue-specific pro-apoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma. *Cell Death Differ* 2006, 13:619-27
3. Sturm I, Bosanquet AG, Radetzki S, Hummel M, Dörken B, Daniel PT. Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation. *Int J Cancer* 2006, 118:2329-36
4. Grabowski P*, Sturm I*, Schelwies K, Maaser K, Buhr HJ, Zeitz M, Dörken B, Daniel PT, Scherübl H. Analysis of neuroendokrine differentiation and the p53/Bax pathway in UICC stage III colorectal carcinoma identifies patients with good prognosis. *Int J Colorect Dis* 2006, 21:221-30. * geteilte Erstautorenschaft
5. Sturm I, Bosanquet AG, Hummel M, Dörken B, Daniel PT. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. *BMC Cancer* 2005; 5: 105
6. Sturm I, Bosanquet AG, Hermann S, Güner D, Dörken B, Daniel PT. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. *Cell Death Differ* 2003;10:477-84.
7. Rau B*, Sturm I*, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B, Daniel PT. Dynamic expression profile of p21^{WAF1/CIP1} and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. *J Clin Oncol* 2003;21:3391-401. *geteilte Erstautorenschaft
8. Schelwies K*, Sturm I*, Grabowski P, Scherübl H, Schindler I, Hermann S, Stein H, Buhr HJ, Riecken EO, Zeitz M, Dörken B, Daniel PT. Analysis of p53/Bax in primary colorectal carcinoma: low Bax protein expression is a negative prognostic factor in UICC stage III tumors. *Int J Cancer* 2002;99:589-96. *geteilte Erstautorenschaft
9. Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT. Analysis of p53/Bax/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high Bax and p16(INK4a/CDKN2) identifies patients with good prognosis. *J Clin Oncol* 2001;19:2272-81.
10. Sturm I, Papadopoulos S, Hillebrand T, Benter T, Luck HJ, Wolff G, Dörken B, Daniel PT. Impaired Bax protein expression in breast cancer: mutational analysis of the Bax and the p53 gene. *Int J Cancer* 2000;87:517-21.
11. Sturm I, Köhne CH, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT. Analysis of the p53/Bax pathway in colorectal cancer: low Bax

is a negative prognostic factor in patients with resected liver metastases. *J Clin Oncol* 1999;17:1364-74.

Kasuistiken

1. Sturm I, Kirschke S, Krahl D, Dörken B. Panhypopituitarism in a patient with breast cancer. *Onkologie* 2004;27:480-2.
2. Sturm I, Watschinger B, Geissler K, Guber SE, Popow-Kraupp T, Hörl WH, Pohanka E. Chronic parvovirus B19 infection-associated pure red cell anaemia in a kidney transplant recipient. *Nephrol Dial Transplant* 1996;11:1367-70.

Koautorenschaften Originalarbeiten

1. Mrozek A, Petrowsky H, Sturm I, Kraus J, Hermann S, Hauptmann S, Lorenz M, Dörken B, Daniel PT. Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability. *Cell Death Differ* 2003;10:461-7
2. Güner D, Sturm I, Hemmati P, Hermann S, Hauptmann S, Wurm R, Budach V, Dörken B, Lorenz M, Daniel PT. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. *Int J Cancer* 2003;103:445-54.
3. Radetzki S, Köhne CH, von Haefen C, Gillissen B, Sturm I, Dörken B, Daniel PT. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. *Oncogene* 2002;21:227-38.
4. Bosanquet AG, Sturm I, Wieder T, Essmann F, Bosanquet MI, Head DJ, Dörken B, Daniel PT. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. *Leukemia* 2002;16:1035-44.
5. Raisova M, Hossini AM, Eberle J, Riebeling C, Wieder T, Sturm I, Daniel PT, Orfanos CE, Geilen CC. The Bax/Bcl-2 ratio determines the susceptibility of human melanoma cells to CD95/Fas-mediated apoptosis. *J Invest Dermatol* 2001;117:333-40.
6. Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C, Köhne CH, Hillebrand T, Daniel PT, Fong Y, Lorenz M. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. *Eur J Surg Oncol* 2001;27:80-7.
7. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dörken B, Daniel PT. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. *Int J Cancer* 2001;92:805-11.
8. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig WD, Henze G, Dörken B, Daniel PT. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. *Leukemia* 2000;14:1606-13.

9. Daniel PT, Sturm I, Ritschel S, Friedrich K, Dörken B, Bendzko P, Hillebrand T. Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. *Anal Biochem* 1999;266:110-5.
10. Daniel PT, Pun KT, Ritschel S, Sturm I, Holler J, Dörken B, Brown R. Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice. *Blood* 1999;94:1100-7.
11. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B, Pezzutto A. Immunotherapy of B-cell lymphoma with CD3x19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody-targeted cytotoxic T cells. *Blood* 1998;92:4750-7.
12. Daniel PT, Kroidl A, Cayeux S, Scholz C, Sturm I, Blankenstein T, Pezzutto A, Dörken B. Retroviral B7.1 gene transfer in cancer cells protects cytotoxic T cells from deletion by "veto" apoptosis. *Adv Exp Med Biol* 1998;451:265-76.
13. Klauser RM, Irschik H, Kletzmayer J, Sturm I, Brunner W, Woloszczuk W, Kovarik J. Pharmacokinetic cyclosporine A profiles under long-term Neoral treatment in renal transplant recipients: does fat intake still matter? *Transplant Proc* 1997;29:3137-40.
14. Fichter J, Stahl CA, Sturm I, Sybrecht GW. A new method for data presentation in incremental cardiorespiratory exercise testing. *Eur J Appl Physiol* 1997;76:532-7.
15. Klauser R, Irschik H, Kletzmayer J, Sturm I, Brunner W, Woloszczuk W, Kovarik J. Neoral-a new microemulsion formula of cyclosporine A: interpatient pharmacokinetic variability in renal transplant recipients. *Transplant Proc* 1995;27:3427-9.

Übersichten und Buchbeiträge

1. Daniel PT, Sturm I, Hemmati PG, Güner D. Pharmakogenomik maligner Tumoren: Bedeutung von Zellzyklus- und Apoptosedefekten für Therapieansprechen und Krankheitsprognose. *Der Onkologe* 2003;10:46-54.
2. Daniel PT, Gillissen B, Sturm I. Tumour Genotype and Response to Cytotoxic Gene Therapy. In: Subramanian G, ed. *Manufacturing of Gene Therapeutics. Methods, Processing, Regulation, and Validation* New York, Boston, Dordrecht, London, Moscow: Kluwer Academic/Plenum Publishers, 2002:59-98.
3. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. *Leukemia* 2001;15:1022-32.

Kongresspublikation

1. Sturm I, Daniel P, Güner D. Analyse von Zellzyklus- und Apoptose-Checkpunkten: Diagnose der klinischen Resistenz maligner Tumore. *MedReview* (<http://www.blackwell.de>) 04/2004: 6-7.